arrow
A

Amitkumar Mehta

h university of alabama at birmingham
H指数:31
被引数:5,645

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma

纳武利尤单抗联合 Brentuximab Vedotin 治疗复发/难治性弥漫性大B细胞淋巴瘤

2025-12-100
OAAI
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma

功能基因组学和肿瘤微环境分析揭示了套细胞淋巴瘤中的预后生物学亚型

2025-11-050
OA
PROs versus clinician-reported adverse events in a large clinical trial: findings from the Phase 3 POLARIX study

患者报告结果(PROs)与临床医生报告的不良事件在大型临床试验中的比较:来自III期POLARIX研究的结果

Blood
IF23.1
2025-09-290
OA
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma

I/II期研究:Subasumstat(TAK-981)联合利妥昔单抗治疗复发/难治性非霍奇金淋巴瘤

2025-05-030
OAAI
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

Nivolumab联合brentuximab vedotin治疗复发/难治性外周T细胞淋巴瘤和皮肤T细胞淋巴瘤

2024-05-201
OAAI
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium
2023-12-162
OAAI
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
2023-12-135
OAAI
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
2023-12-1018
OAAI
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Mosunetuzumab联合CHOP治疗未经治疗的DLBCL: 2期研究的安全性和有效性结果

2023-10-1110
OAAI
Lacutamab in patients with mycosis fungoides: efficacy results according to updated lymph node classification in the TELLOMAK study
2023-09-010
PRE
Parsaclisib, a PI3Kd inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study

Parsaclisib,一种PI3Kd抑制剂,用于复发和难治性套细胞淋巴瘤 (CITADEL-205): 一项2期研究

2023-08-014
OAAI
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas

SEA-CD40的1期剂量递增研究: 非岩藻糖基化CD40激动剂,用于晚期实体瘤和淋巴瘤

2023-06-2910
OAAI
PHASE 1 STUDY OF SEA-TGT, A HUMAN, NONFUCOSYLATED ANTI-TIGIT MONOCLONAL ANTIBODY WITH ENHANCED IMMUNE-EFFECTOR FUNCTION, IN PATIENTS WITH ADVANCED MALIGNANCIES (SGNTGT-001, TRIAL IN PROGRESS)
2021-11-101
OA